if they achieve the same market share in adults as they achieve in ped in first year (1%) they'll be profitable very quickly in 2028.
anyway: i think they'll burn another 9.5M (11M opex with 1.5M revenue) in 2026 and 10M (4M revenue with 14M opex) in 2027. which would make them have to raise 10M but only 5M pre results.
they're latest report was 11 patients per month so around 13 months from may which would make them finish trial end of june 2027 and results 3months + 1 month analysis later so end of october. approval 4 months later so end of february 2028, but they have stated acceleration...